Immunophotonics has reached a major milestone in its clinical development efforts with the completion of treatment for the final patient in the INJECTABL-1 Phase 1b/2a trial of IP-001 for advanced solid tumors.
The 41-patient, multicenter trial was conducted across the U.S., UK, France, Germany, and Switzerland, targeting colorectal cancer, non-small cell lung cancer, and soft tissue sarcoma. IP-001, our proprietary glycan polymer, is designed to transform routine tumor ablation into a personalized systemic cancer immunotherapy.
We thank our partners, investigators, and especially all patients who made this milestone possible.